Advice
in the absence of a submission from the holder of the marketing authorisation:
eslicarbazepine acetate (Zebinix ®) is not recommended for use within NHSScotland.
Indication under review: As monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice45KB (PDF)
Medicine details
- Medicine name:
- eslicarbazepine acetate (Zebinix)
- SMC ID:
- SMC2090
- Indication:
- As monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy.
- Pharmaceutical company
- Eisai Ltd
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 June 2018